Skip to content

Trigeminovascular effects of propranolol in migraine treatment

Trigeminovascular effects of propranolol in migraine treatment - TREPMI

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43388
Enrollment
22
Registered
2016-03-30
Start date
2017-02-21
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Oral administration of propranolol 80mg (oral solution)

Sponsors

Inwendige Geneeskunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 64 years Non-smoking for more than 6 months Females should use an oral contraceptive pill Body mass index between 19 and 28 kg/m^2 Capable and willing to give informed consent General good health, based on medical history and physical examination

Exclusion criteria

Exclusion criteria: History of cardiovascular disease History of migraine Previous history of asthma or use of bronchodilators. Blood pressure

Design outcomes

Primary

MeasureTime frame
Changes in dermal blood flow response to capsaicin application and saline iontophoresis, after propranolol intake.

Secondary

MeasureTime frame
Changes in blood pressure after propranolol use.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)